Gaelic Laboratories and Athlone Laboratories have announced a dual-source supply strategy for Beta-Lactam antibiotics, giving customers the ability to source identical products from either of the companies' two Irish manufacturing sites, reducing reliance on single-site production for a class of medicines where supply continuity is critical.

The strategy follows Gaelic Laboratories' acquisition of Athlone Laboratories in December 2025, a horizontal deal bringing together two GMP-approved manufacturers of oral-dose Beta-Lactam products, and marks the second phase of post-acquisition integration, after an initial phase covering operational changes, internal communications and a joint website.

General manager Brian Morrissey said both companies benefit from a strategic investment and expansion programme that continuously improves their technology base, with both sites being upgraded to comply with the latest AMR Industry Alliance Manufacturing Standard. He said the companies had also strengthened technology transfer protocols so customers can be confident the Beta-Lactams they manufacture are produced consistently, to the same standards, across both sites.

Gaelic Laboratories and Athlone Laboratories are Irish GMP-approved manufacturers of oral-dose Beta-Lactam antibiotics; their combined operation has annual capacity for 1.2 billion oral dosage forms and serves customers across Ireland, the UK, the EU, MENA, Canada and Australia.

"We are launching the dual source strategy at CPHI Milan in October," Morrissey said, adding that the companies' exhibition stand would showcase the strengths and capabilities of both businesses to existing customers and new prospects interested in the future of Beta-Lactam production in Ireland.

The dual-source strategy reflects a wider push in generic pharmaceutical manufacturing towards resilience-centric supply models, as customers increasingly weigh geographic and single-site concentration risk alongside cost when selecting suppliers.

The timing reflects structural pressure across the beta-lactam supply chain, a global market worth around $31.8bn in 2025 and forecast to reach $37.3bn by 2032, where production remains heavily concentrated in a small number of geographies.

For the sector, dual-sourcing from two sites within a single group, rather than from independent competitors, gives Gaelic and Athlone a differentiated resilience offering without the contractual complexity of managing external backup suppliers.

The wider signal for the sector is that post-acquisition manufacturing integration in pharma is increasingly marketed as a customer-facing resilience feature, rather than treated purely as an internal cost-synergy exercise.

Source: Manufacturing Chemist / Reanin / GII Research